Compugen Reports Fourth Quarter and Full Year 2023 Results

Partnership with Gilead on preclinical immuno-oncology program further validates Compugen’s computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple data readouts and updates planned from Compugen’s diversified portfolio Solid balance sheet…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks